Please login to the form below

Not currently logged in


This page shows the latest AFFiRiS news and features for those working in and with pharma, biotech and healthcare.

Another Alzheimer’s failure as Targacept trial disappoints

Another Alzheimer’s failure as Targacept trial disappoints

This June the UK's Medical Research Council (MRC) launched a £16m dementia research programme and Austrian biopharma company AFFiRiS claimed its drug candidate AD04 was the first therapy to show

Latest news

  • Burden of proof Burden of proof

    So AFFiRiS' recently announced 'breakthrough' should be a cause for celebration. ... And although AFFiRiS says AD04's results are the first ever to meet EMA and FDA criteria for disease modifications in Alzheimer's, the trial was not a controlled study

  • AFFiRiS claims a first in Alzheimer's disease therapy AFFiRiS claims a first in Alzheimer's disease therapy

    AFFiRiS, however, believes its data reveals a more profound impact using its vaccination approach. ... AFFiRiS' R&D approach is to develop a portfolio of peptide vaccines against various forms of a drug target like beta-amyloid and test them in parallel.

  • Ali Alloueche to lead business strategy at Austrian biopharma Affiris

    In his new role Alloueche will oversee Affiris' business activities, strategic alliances and partnerships. ... Alloueche said: "Affiris is one of the most dynamic biopharmaceutical companies in Europe.

  • AFFiRiS Alzheimer vaccine begins efficacy trial

    AFFiRiS' Alzheimer's vaccine candidate AD02 has begun phase II clinical testing, with hopeful efficacy confirmation by 2012. ... Vienna-based AFFiRiS' Alzheimer's vaccine candidate AD02 has begun phase II clinical testing - the hope being that

  • GSK Biologicals signs Alzheimer's deal with AFFiRiS

    The vaccines, which are currently under Phase I clinical development, are being developed using the AFFiRiS' AFFiTOPE technology. ... The deal will see AFFiRIS receive an up-front payment of £17.5m with the possibility of future milestone and royalty

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...